Adu, D., Howie, A. J., Scott, D. G., et al. 1987. Polyarteritis and the kidney. Q J Med 62, 221–37.Google Scholar

Agard, C., Mouthon, L., Mahr, A., Guillevin, L. 2003. Microscopic polyangiitis and polyarteritis nodosa: How and when do they start? Arthritis Rheum 49, 709–15.Google Scholar

Albert, D. A., Rimon, D., Silverstein, M. D. 1988. The diagnosis of polyarteritis nodosa. I. A literature-based decision analysis approach. Arthritis Rheum 31, 1117–27.Google Scholar

Ara, J., Mirapeix, E., Rodriguez, R., Saurina, A., Darnell, A. 1999. Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. Nephrol Dial Transplant 14, 1667–72.Google Scholar

Baggenstoss, A. H., Shick, R. M., Polley, H. F. 1951. The effect of cortisone on the lesions of periarteritis nodosa. Am J Pathol 27, 537.Google ScholarPubMed

Balow, J. E. 1985. Renal vasculitis. Kidney Int 27, 954–64.CrossRefGoogle ScholarPubMed

Bansal, P. J., Tobin, M. C. 2004. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 93, 398–401.Google Scholar

Beck, L., Bomback, A. S., Choi, M. J., et al. 2013. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis 62, 403–41.CrossRefGoogle ScholarPubMed

Begier, E. M., Langford, C. A., Sneller, M. C., Wise, R. P., Ball, R. 2004. Polyarteritis nodosa reports to the vaccine adverse event reporting system (VAERS): Implications for assessment of suspected vaccine-provoked vasculitis. J Rheumatol, 31, 2181–8.Google Scholar

Bendo, E., Gilbert, M., Chavis, P., Mistr, S. 2009. Sherlock Holmes in the ER (the case of red and the head). Surv Ophthalmol 54, 128–34.Google Scholar

Bonsib, S. M. 2001. Polyarteritis nodosa. Semin Diagn Pathol 18, 14–23.Google ScholarPubMed

Bourgarit, A., Le Toumelin, P., Pagnoux, C., et al. 2005. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg–Strauss syndrome: A retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 84, 323–30.Google Scholar

Bouvard, B., Lavigne, C., Marc, G., et al. 2007. Two consecutive episodes of intracerebral hemorrhage as the presenting feature of polyarteritis nodosa. Rev Med Interne 28, 651–4.Google ScholarPubMed

Brown, M. M., Swash, M. 1989. Polyarteritis nodosa and other systemic vasculitides. Handbook of Clinical Neurology 11, 353–67.Google Scholar

Caldeira, T., Meireles, C., Cunha, F., et al. 2007. Systemic polyarteritis nodosa associated with acute Epstein–Barr virus infection. Clin Rheumatol 26, 1733–5.Google Scholar

Carpenter, M. T., West, S. G. 1994. Polyarteritis nodosa in hairy cell leukemia: Treatment with interferon-alpha. J Rheumatol 21, 1150–2.Google ScholarPubMed

Chanseaud, Y., García de la Peña-Lefebvre, P., Guilpain, P., et al. 2003. IgM and IgG autoantibodies from microscopic polyangiitis patients but not those with other small- and medium-sized vessel vasculitides recognize multiple endothelial cell antigens. Clin Immunol 109, 165–78.CrossRefGoogle Scholar

Chen, N. C., Lai, P. H., Fang, H. C., Chou, K. J., Chen, C. L. 2012. Microscopic polyangiitis with an initial presentation of pontine infarction. Am J Med Sci 344, 163–5.Google Scholar

Chetty, R. 2001. Vasculitides associated with HIV infection. J Clin Pathol 54, 275–8.CrossRefGoogle ScholarPubMed

Chin, R. L., Latov, N. 2005. Central nervous system manifestations of rheumatologic diseases. Curr Opin Rheumatol 17, 91–9.Google ScholarPubMed

Cohen, R. D., Conn, D. L., Ilstrup, D. M. 1980. Clinical features, prognosis, and response to treatment in polyarteritis. Mayo Clin Proc 55, 146–55.Google ScholarPubMed

Coll-Vinent, B., Grau, J. M., López-Soto, A., et al. 1997. Circulating soluble adhesion molecules in patients with classical polyarteritis nodosa. Br J Rheumatol 36, 1178–83.CrossRefGoogle ScholarPubMed

Colmegna, I., Maldonado-Cocco, J. A. 2005. Polyarteritis nodosa revisited. Curr Rheumatol Rep 7, 288–96.CrossRefGoogle ScholarPubMed

Conn, D. L. 1990. Polyarteritis. Rheum Dis Clin North Am 16, 341–62.Google Scholar

Daoud, M. S., Gibson, L. E., DeRemee, R. A., et al. 1994. Cutaneous Wegener’s granulomatosis: Clinical, histopathologic, and immunopathologic features of thirty patients. J Am Acad Dermatol 31, 605–12.Google Scholar

Das, C. J., Pangtey, G. S. 2006. Images in clinical medicine. Arterial microaneurysms in polyarteritis nodosa. N Engl J Med 355, 2574.Google Scholar

Deshpande, P. V., Gilbert, R., Alton, H., Milford, D. V. 2000. Microscopic polyarteritis with renal and cerebral involvement. Pediatr Nephrol 15, 134–5.Google Scholar

Fauci, A. S., Doppman, J. L., Wolff, S. M. 1978. Cyclophosphamide-induced remissions in advanced polyarteritis nodosa. Am J Med 64, 890–4.Google Scholar

Fechner, F. P., Faquin, W. C., Pilch, B. Z. 2002. Wegener’s granulomatosis of the orbit: A clinicopathological study of 15 patients. Laryngoscope 112, 1945–50.Google Scholar

Filer, A. D., Gardner-Medwin, J. M., Thambyrajah, J., et al. 2003. Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis 62, 162–7.CrossRefGoogle ScholarPubMed

Ford, R. G., Siekert, R. G. 1965. Central nervous system manifestations of periarteritis nodosa. Neurology 15, 114–22.Google Scholar

Freire, A. L., Bertolo, M. B., de Pinho, A. J., Samara, A. M., Fernandes, S. R. 2004. Increased serum levels of interleukin-8 in polyarteritis nodosa and Behçet’s disease. Clin Rheumatol 23, 203–5.Google Scholar

Frohnert, P. P., Sheps, S. G. 1967. Long-term follow-up study of periarteritis nodosa. Am J Med 43, 8–14.CrossRefGoogle ScholarPubMed

Gayraud, M., Guillevin, L., le Toumelin, P., et al. 2001. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg–Strauss syndrome: Analysis of four prospective trials including 278 patients. Arthritis Rheum 44, 666–75.Google Scholar

Gherardi, R., Belec, L., Mhiri, C., et al. 1993. The spectrum of vasculitis in human immunodeficiency virus-infected patients. A clinicopathologic evaluation. Arthritis Rheum 36, 1164–74.CrossRefGoogle ScholarPubMed

Gocke, D. J., Hsu, K., Morgan, C., et al. 1970. Association between polyarteritis and Australia antigen. Lancet 2, 1149–53.Google Scholar

Gordon, M., Luqmani, R. A., Adu, D., et al. 1993. Relapses in patients with a systemic vasculitis. Q J Med 86, 779–89.Google Scholar

De Groot, K., Rasmussen, N., Bacon, P. A., et al. 2005. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52, 2461–9.Google Scholar

Guillevin, L. 1999. Treatment of classic polyarteritis nodosa in 1999. Nephrol Dial Transplant 14, 2077–9.Google Scholar

Guillevin, L. 2004. Virus-induced systemic vasculitides: New therapeutic approaches. Clin Dev Immunol 11, 227–31.Google Scholar

Guillevin, L., Cohen, P., Mahr, A., et al. 2003. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 49, 93–100.Google Scholar

Guillevin, L., Lhote, F. 1998. Treatment of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 41, 2100–5.Google Scholar

Guillevin, L., Lhote, F., Cohen, P., et al. 1995. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg–Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 38, 1638–45.Google Scholar

Guillevin, L., Lhote, F., Amouroux, J., et al. 1996. Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathologic findings in polyarteritis nodosa and Churg–Strauss syndrome: Indications for the classification of vasculitides of the polyarteritis nodosa group. Br J Rheumatol 35, 958–64.CrossRefGoogle ScholarPubMed

Guillevin, L., Lhote, F., Gherardi, R. 1997. Polyarteritis nodosa, microscopic polyangiitis, and Churg–Strauss syndrome: Clinical aspects, neurologic manifestations, and treatment. Neurol Clin 15, 865–86.CrossRefGoogle ScholarPubMed

Guillevin, L., Lhote, F., Jarrousse, B., Fain, O. 1992. Treatment of polyarteritis nodosa and Churg–Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years. Ann Med Interne (Paris) 143, 405–16.Google Scholar

Guillevin, L., Mahr, A., Callard, P., et al. 2005. Hepatitis B virus-associated polyarteritis nodosa: Clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 84, 313–22.CrossRefGoogle ScholarPubMed

Guillevin, L., Pagnoux, C., Karras, A., et al. 2014. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371, 1771–80.Google Scholar

Guillevin, L., Pagnoux, C., Seror, R., et al. 2011. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90, 19–27.Google Scholar

Gupta, V., Chinchure, S. D., Goe, G., et al. 2013. Coil embolization of intracranial aneurysm in polyarteritis nodosa. A case report and review of the literature. Interv Neuroradiol 19, 203–8.Google Scholar

Han, S., Rehman, H. U., Jayaratne, P. S., Carty, J. E. 2006. Microscopic polyangiitis complicated by cerebral haemorrhage. Rheumatol Int 26, 1057–60.Google Scholar

Harlé, J. R., Disdier, P., Ali Cherif, A., et al. 1991. Curable dementia and panarteritis nodosa. Rev Neurol (Paris) 147, 148–50.Google Scholar

Harper, S. L., Letko, E., Samson, C. M., et al. 2001. Wegener’s granulomatosis: The relationship between ocular and systemic disease. J Rheumatol 28, 1025–32.Google ScholarPubMed

Hasler, P., Kistler, H., Gerber, H. 1995. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum 25, 134–42.CrossRefGoogle ScholarPubMed

Haugeberg, G., Bie, R., Bendvold, A., Larsen, A. S., Johnsen, V. 1998. Primary vasculitis in a Norwegian community hospital: A retrospective study. Clin Rheumatol 17, 364–8.Google Scholar

Hekali, P., Kajander, H., Pajari, R., Stenman, S., Somer, T. 1991. Diagnostic significance of angiographically observed visceral aneurysms with regard to polyarteritis nodosa. Acta Radiol 32, 143–8.CrossRefGoogle ScholarPubMed

Hiemstra, T. F., Walsh, M., Mahr, A., et al. 2010. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial. JAMA 304, 2381–8.CrossRefGoogle ScholarPubMed

Hirohata, S., Tanimoto, K., Ito, K. 1993. Elevation of cerebrospinal fluid interleukin-6 activity in patients with vasculitides and central nervous system involvement. Clin Immunol Immunopathol 66, 225–9.Google Scholar

Hogan, S. L., Falk, R. J., Chin, H., et al. 2005. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143, 621–31.Google Scholar

Hogan, S. L., Nachman, P. H., Wilkman, A. S., Jennette, J. C., Falk, R. J. 1996. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7, 23–32.Google Scholar

Honda, H., Hasegawa, T., Morokawa, N., Kato, N., Inoue, K. 1996. A case of MPO-ANCA related vasculitis with transient leukoencephalopathy and multiple cerebral hemorrhage. Rinsho Shinkeigaku 36, 1089–94.Google ScholarPubMed

Iaconetta, G., Benvenuti, D., Lamaida, E., et al. 1994. Cerebral hemorrhagic complication in polyarteritis nodosa. Case report and review of the literature. Acta Neurol (Napoli) 16, 64–9.Google Scholar

Ito, Y., Suzuki, K., Yamazaki, T., et al. 2006. ANCA-associated vasculitis (AAV) causing bilateral cerebral infarction and subsequent intracerebral hemorrhage without renal and respiratory dysfunction. J Neurol Sci 240, 99–101.Google Scholar

Jayne, D. 2009. The diagnosis of vasculitis. Best Pract Res Clin Rheumatol 23, 445–53.Google Scholar

Jayne, D., Rasmussen, N., Andrassy, K., et al. 2003. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349, 36–44.Google Scholar

Jayne, D. R., Gaskin, G., Pusey, C. D., Lockwood, C. M. 1995. ANCA and predicting relapse in systemic vasculitis. QJM 88, 127–33.Google ScholarPubMed

Jayne, D. R., Gaskin, G., Rasmussen, N., et al. 2007. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18, 2180–8.Google Scholar

Jennette, J. C., Falk, R. J. 1997. Small-vessel vasculitis. N Engl J Med 337, 1512–23.Google Scholar

Jennette, J. C., Falk, R. J., Andrassy, K., et al. 1994. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37, 187–92.CrossRefGoogle ScholarPubMed

Jennette, J. C., Falk, R. J., Bacon, P. A., et al. 2013. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 65, 1–11.Google Scholar

Jennette, J. C., Thomas, D. B., Falk, R. J. 2001. Microscopic polyangiitis (microscopic polyarteritis). Semin Diagn Pathol 18, 3–13.Google Scholar

Jones, R. B., Tervaert, J. W., Hauser, T., et al. 2010. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363, 211–20.Google Scholar

Kallenberg, C. G. 2007. Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Curr Opin Rheumatol 19, 17–24.Google Scholar

Kallenberg, C. G., Heeringa, P., Stegeman, C. A. 2006. Mechanisms of disease: Pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2, 661–70.Google Scholar

Kamimura, T., Hatakeyama, M., Torigoe, K., et al. 2005. Muscular polyarteritis nodosa as a cause of fever of undetermined origin: A case report and review of the literature. Rheumatol Int 25, 394–7.Google Scholar

Kaplan, A. A. 2003. The use of apheresis in immune renal disorders. Ther Apher Dial 7, 165–72.Google Scholar

Kasantikul, V., Suwanwela, N., Pongsabutr, S. 1991. Magnetic resonance images of brain stem infarct in periarteritis nodosa. Surg Neurol 36, 133–6.Google Scholar

Kirkland, G. S., Savige, J., Wilson, D., et al. 1997. Classical polyarteritis nodosa and microscopic polyarteritis with medium vessel involvement: A comparison of the clinical and laboratory features. Clin Nephrol 47, 176–80.Google Scholar

Koppensteiner, R., Base, W., Bognar, H., et al. 1989. Course of cerebral lesions in a patient with periarteritis nodosa studied by magnetic resonance imaging. Klin Wochenschr 67, 398–401.Google Scholar

Kussmaul, A., Maier, R. 1866. Ueber eine bisher nicht beschriebene eigenthümliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellähmung einhergeht. Dtsch Arch Klin Med 1, 484–518.Google Scholar

de la Fuente Fernandez, R., Graña Gil, J. 1994. Anticardiolipin antibodies and polyarteritis nodosa. Lupus 3, 523–4.Google Scholar

Lane, S. E., Watts, R., Scott, D. G. 2005. Epidemiology of systemic vasculitis. Curr Rheumatol Rep 7, 270–5.Google Scholar

Laurino, S., Chaudhry, A., Booth, A., Conte, G., Jayne, D. 2010. Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol Dial Transplant 25, 3307–14.Google Scholar

Leib, E. S., Restivo, C., Paulus, H. E. 1979. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 67, 941–7.Google Scholar

Lhote, F., Cohen, P., Généreau, T., Gayraud, M., Guillevin, L. 1996. Microscopic polyangiitis: Clinical aspects and treatment. Ann Med Interne (Paris) 147, 165–77.Google Scholar

Lhote, F., Cohen, P., Guillevin, L. 1998. Polyarteritis nodosa, microscopic polyangiitis and Churg–Strauss syndrome. Lupus 7, 238–58.Google Scholar

Lhote, F., Guillevin, L. 1995. Polyarteritis nodosa, microscopic polyangiitis, and Churg–Strauss syndrome. Clinical aspects and treatment. Rheum Dis Clin North Am 21, 911–47.Google Scholar

Lightfoot, R. W., Michel, B. A., Bloch, D. A., et al. 1990. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33, 1088–93.Google Scholar

Long, S. M., Dolin, P. 1994. Polyarteritis nodosa presenting as acute blindness. Ann Emerg Med 24, 523–5.Google Scholar

MacLaren, K., Gillespie, J., Shrestha, S., Neary, D., Ballardie, F. W. 2005. Primary angiitis of the central nervous system: Emerging variants. QJM 98, 643–54.Google Scholar

Mahr, A., Guillevin, L., Poissonnet, M., Aymé, S. 2004. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg–Strauss syndrome in a French urban multiethnic population in 2000: A capture–recapture estimate. Arthritis Rheum 51, 92–9.Google Scholar

Mandell, B. F., Calabrese, L. H. 1998. Infections and systemic vasculitis. Curr Opin Rheumatol 10, 51–7.Google Scholar

Marignier, R., Derex, L., Philippeau, F., et al. 2002. Anterior choroidal artery infarction revealing polyarteritis nodosa. Rev Neurol (Paris) 158, 221–4.Google Scholar

Mayo, J., Arias, M., Leno, C., Berciano, J. 1986. Vascular parkinsonism and periarteritis nodosa. Neurology 36, 874–5.Google Scholar

Moore, P. M. 1995. Neurologic manifestation of vasculitis: Update on immunopathogenic mechanisms and clinical features. Ann Neurol 37 Suppl 1, S131–41.CrossRefGoogle Scholar

Moore, P. M., Cupps, T. R. 1983. Neurological complications of vasculitis. Ann Neurol 14, 155–67.Google Scholar

Moore, P. M., Fauci, A. S. 1981. Neurologic manifestations of systemic vasculitis. A retrospective and prospective study of the clinicopathologic features and responses to therapy in 25 patients. Am J Med 71, 517–24.Google Scholar

Mukhtyar, C., Guillevin, L., Cid, M. C., et al. 2009. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68, 310–7.Google Scholar

Nachman, P. H., Hogan, S. L., Jennette, J. C., Falk, R. J. 1996. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7, 33–9.Google Scholar

Navon Elkan, P., Pierce, S. B., Segel, R., et al. 2014. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370, 921–31.Google Scholar

Niles, J. L., Böttinger, E. P., Saurina, G. R., et al. 1996. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med 156, 440–5.Google Scholar

Oran, I., Memis, A., Parildar, M., Yunten, N. 1999. Multiple intracranial aneurysms in polyarteritis nodosa: MRI and angiography. Neuroradiology 41, 436–9.Google Scholar

Ozkul, A., Tataroglu, C., Kiylioglu, N., Akyol, A., Tataroglu, C. 2011. Microscopic polyangiitis presenting with medullary infarct. J Neurol Sci 300, 173–5.Google Scholar

Pagnoux, C., Cohen, P., Guillevin, L. 2006. Vasculitides secondary to infections. Clin Exp Rheumatol 24, S71–81.Google Scholar

Pagnoux, C., Mahr, A., Hamidou, M. A., et al. 2008. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359, 2790–803.CrossRefGoogle ScholarPubMed

Pagnoux, C., Seror, R., Henegar, C., et al. 2010. Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group database. Arthritis Rheum 62, 616–26.Google Scholar

Pavone, L., Grasselli, C., Chierici, E., et al. 2006. Outcome and prognostic factors during the course of primary small-vessel vasculitides. J Rheumatol 33, 1299–306.Google ScholarPubMed

Ramos-Casals, M., Muñoz, S., Medina, F., et al. 2009. Systemic autoimmune diseases in patients with hepatitis C virus infection: Characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 36, 1442–8.Google Scholar

Reichart, M. D., Bogousslavsky, J., Janzer, R. C. 2000. Early lacunar strokes complicating polyarteritis nodosa: Thrombotic microangiopathy. Neurology 54, 883–9.Google Scholar

Reichart, M. D., Meuli, R., Bogousslavsky, J., 2008. Microscopic polyangiitis and polyarteritis nodosa. In Uncommon Causes of Stroke, 2nd edn, ed. Caplan, L. R.. Cambridge: Cambridge University Press, pp. 311–30.Google Scholar

Ribi, C., Cohen, P., Pagnoux, C., et al. 2010. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 62, 1186–97.Google Scholar

Rodgers, H., Guthrie, J. A., Brownjohn, A. M., Turney, J. H. 1989. Microscopic polyarteritis: Clinical features and treatment. Postgrad Med J 65, 515–8.Google Scholar

Rumboldt, Z., Kalousek, M., Castillo, M. 2003. Hyperacute subarachnoid hemorrhage on T2-weighted MR images. AJNR Am J Neuroradiol 24, 472–5.Google Scholar

Sack, M., Cassidy, J. T., Bole, G. G. 1975. Prognostic factors in polyarteritis. J Rheumatol 2, 411–20.Google Scholar

Sasaki, A., Hirato, J., Nakazato, Y., Tanaka, T., Takeuchi, H. 1998. An autopsy case of P-ANCA-positive microscopic polyangiitis with multiple cerebral hemorrhagic infarction. No To Shinkei 50, 56–60.Google ScholarPubMed

Savage, C. O., Winearls, C. G., Evans, D. J., Rees, A. J., Lockwood, C. M. 1985. Microscopic polyarteritis: Presentation, pathology and prognosis. Q J Med 56, 467–83.Google Scholar

Savige, J., Gillis, D., Benson, E., et al. 1999. International Group for Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 111, 507–51.Google Scholar

Segelmark, M., Selga, D. 2007. The challenge of managing patients with polyarteritis nodosa. Curr Opin Rheumatol 19, 33–8.CrossRefGoogle ScholarPubMed

Specks, U. 2015. Accurate relapse prediction in ANCA-associated vasculitis: The search for the Holy Grail. J Am Soc Nephrol: JASN 26, 505–7.Google Scholar

Squire, I. B., Grosset, D. G., Lees, K. R. 1993. Immunosuppressive treatment in stroke and renal failure. Ann Rheumat Dis 52, 165.Google Scholar

Stahl, H., Mihatsch, M. J., Orantes, M., Lehmann, F. 1995. Pneumonia, biclonal gammopathy, paralysis of the fibular nerve and cerebrovascular insult. Praxis (Bern 1994) 84, 1071–8.Google Scholar

Stanson, A. W., Friese, J. L., Johnson, C. M., et al. 2001. Polyarteritis nodosa: Spectrum of angiographic findings. Radiographics 21, 151–9.Google Scholar

Stegeman, C. A. 2002. Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis. Nephrol Dial Transplant 17, 2077–80.Google Scholar

Stone, J. H. 2002. Polyarteritis nodosa. JAMA 288, 1632–9.Google Scholar

Stone, J. H., Hoffman, G. S., Merkel, P. A., et al. 2001. A disease-specific activity index for Wegener’s granulomatosis: Modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 44, 912–20.Google Scholar

Stone, J. H., Merkel, P. A., Spiera, R., et al. 2010. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363, 221–32.Google Scholar

Tang, C. W., Wang, P. N., Lin, K. P., et al. 2009. Microscopic polyangiitis presenting with capsular warning syndrome and subsequent stroke. J Neurol Sci 277, 174–5.Google Scholar

Tervaert, J. W., Kallenberg, C. 1993. Neurologic manifestations of systemic vasculitides. Rheum Dis Clin North Am 19, 913–40.Google Scholar

Trepo, C., Guillevin, L. 2001. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: The case against autoimmune intervention in pathogenesis. J Autoimmun 16, 269–74.Google Scholar

Trepo, C., Thivolet, J. 1970. Hepatitis associated antigen and periarteritis nodosa (PAN). Vox Sang 19, 410–1.Google Scholar

Walton, E. W. 1958. Giant-cell granuloma of the respiratory tract (Wegener’s granulomatosis). Br Med J 2, 265.Google Scholar

Watts, R. A., Lane, S. E., Bentham, G., Scott, D. G. 2000. Epidemiology of systemic vasculitis: A ten-year study in the United Kingdom. Arthritis Rheum 43, 414–9.Google Scholar

Watts, R. A., Gonzalez-Gay, M. A., Lane, S. E., et al. 2001. Geoepidemiology of systemic vasculitis: Comparison of the incidence in two regions of Europe. Ann Rheum Dis 60, 170–2.Google Scholar

Watts, R. A., Suppiah, R., Merkel, P. A., Luqmani, R. 2011. Systemic vasculitis: is it time to reclassify? Rheumatology 50, 643–5.Google Scholar

Weidner, S., Geuss, S., Hafezi-Rachti, S., Wonka, A., Rupprecht, H. D. 2004. ANCA-associated vasculitis with renal involvement: An outcome analysis. Nephrol Dial Transplant 19, 1403–11.Google Scholar

Westman, K. W., Bygren, P. G., Olsson, H., Ranstam, J., Wieslander, J. 1998. Relapse rate, renal survival, and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 9, 842–52.Google Scholar

Westman, K. W., Selga, D., Isberg, P. E., Bladström, A., Olsson, H. 2003. High proteinase 3–anti-neutrophil cytoplasmic antibody (ANCA) level measured by the capture enzyme-linked immunosorbent assay method is associated with decreased patient survival in ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 14, 2926–33.Google Scholar

Wildhagen, K., Stoppe, G., Meyer, G. J., et al. 1989. Imaging diagnosis of central nervous system involvement in panarteritis nodosa. Z Rheumatol 48, 323–5.Google Scholar

Younger, D. S. 2004. Vasculitis of the nervous system. Curr Opin Neurol 17, 317–36.Google Scholar

Zhou, Q., Yang, D., Ombrello, A. K., et al. 2014. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 370, 911–20.Google Scholar

Ames, PR, Roes, L, Lupoli, S, et al. (1996) Thrombosis in Churg–Strauss syndrome. Beyond vasculitis? British Journal of Rheumatology, 35, 1181–3.Google Scholar

Chang, Y, Kargas, SA, Goates, JJ, Horoupian, DS (1993). Intraventricular and subarachnoid hemorrhage resulting from necrotizing vasculitis of the choroid plexus in a patient with Churg–Strauss syndrome. Clinical Neuropathology, 12, 84–7.Google Scholar

Cheng, M, Huang, P, Liao, P, Chen, J, Chiang, T (2012). Acta Neurologica Taiwanica, 21 No 4.Google Scholar

Churg, J, Strauss, L (1951). Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. American Journal of Pathology, 27, 277–301.Google Scholar

Chumbley, LC, Harrison, EG, DeRemee, RA (1977). Allergic granulomatosis and angiitis (Churg–Strauss syndrome). Mayo Clinic Proceedings, 52, 477–84.Google ScholarPubMed

Dorfman, LJ, Ransom, BR, Formo, LS, Klets, A (1983). Neuropathy in the hypereosinophilic syndrome. Muscle and Nerve 6, 291–8.Google Scholar

Durack, DT, Sumi, SM, Klebanoff, SJ (1979). Neurotoxicity of human eosinophils. Proceedings of the National Academy of Sciences, USA, 76, 1443–7.CrossRefGoogle ScholarPubMed

Fauci AS, (1982). NIH conference: the idiopathic hypereosinophilic syndrome. Annals of Internal Medicine, 97, 78–92.Google Scholar

Garcia, G, Achouh, L, Cobarzan, D, Fichet, D, Humbert, M, (2005) Severe venous thromboembolic disease in Churg–Strauss syndrome. Allergy, 60, 409–10.Google Scholar

Guillevin L, , Lhote F, , Gayraud, M, et al. (1996). Prognostic factors in polyarteritis nodosa and Churg–Strauss syndrome. A prospective study in 342 patients. Medicine, 75, 17–28.Google Scholar

Hoffman, PM, Godfrey, T, Stawell, RJ (2005). A case of Churg–Strauss syndrome with visual loss following central retinal artery occlusion. Lupus, 14, 174–5.Google Scholar

Keogh, KA, Specks, U (2003). Churg–Strauss syndrome. Clinical presentation, antineutrophil cytoplasmic antibodies and leukotriene receptor antagonists. American Journal of Medicine, 115, 284–90.Google Scholar

Keogh, KA, Specks, U (2006). Churg–Strauss syndrome: Update on clinical, laboratory and therapeutic aspects. Sarcoidosis, Vasculitis and Diffuse Lung Diseases, 23, 3–12.Google Scholar

Keogh, K (2007). Leukotriene receptor antagonists and Churg–Strauss syndrome: Cause, trigger or merely an association. Drug Safety, 30, 837–43.Google Scholar

Lanham, JG, Elkon, KB, Pusey, CD, Hughes, CR (1984). Systemic vasculitis with asthma and eosinophilia: A clinical approach to the Churg-Strauss Syndrome. Medicine, 63, 65–81.Google Scholar

Liou, HH, Liu, HM, Chiang, IP, Yeh, TS, Chen, RC (1997). Churg–Strauss syndrome presented as multiple intracerebral hemorrhage. Lupus, 6, 279–82.Google Scholar

Masi, AT, Hunder, GG, Lie, JT, et al. (1990). The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis and Rheumatism, 33, 1094–100.Google Scholar

Nishino, R, Murata, Y, Oiwa, H, et al. (1999). A case of Churg–Strauss syndrome presented as right thalamic hemorrhage. No To Shinkei 51, 891–4.Google Scholar

Pagnoux, C, Guilpain, P, Guillevin, L (2007). Churg–Strauss syndrome. Current Opinion in Rheumatology, 19, 25–32.Google Scholar

Peen, E, Hahn, P, Lauwers, G et al. (2000). Churg–Strauss syndrome: Localization of eosinophil major basic protein in damaged tissues. Arthritis and Rheumatology, 43, 1897–900.Google Scholar

Sable-Fourtassou, R, Cohen, P, Mahr, A, et al. for the French Vasculitis Study Group (2005). Antineutrophil cytoplasmic antibodies and the Churg–Strauss syndrome. Annals of Internal Medicine, 143, 632–8.Google Scholar

Sehgal, M, Swanson, JW, Deremee, RA, Colby, TV (1995). Neurologic manifestations of Churg–Strauss syndrome. Mayo Clinic Proceedings, 70, 337–41.Google Scholar

Teresa Sartori, M, Briani, C, Munari, M, et al. (2006). Cerebral venous thrombosis as a rare onset of Churg–Strauss syndrome. Thrombosis and Haemostasis, 96, 90–2.Google Scholar

Tsuda, H, Ishikawa, H, Majima, T, et al. (2005). Isolated oculomotor nerve palsy in Churg–Strauss syndrome. Internal Medicine, 44, 638–40.Google Scholar

Udono, T, Abe, T, Sato, H, Tamai, M (2003). Bilateral central retinal artery occlusion in Churg–Strauss syndrome. American Journal of Ophthalmology, 136, 1181–3.Google Scholar

Abu-Shakra, M. et al., 1995. Anticardiolipin antibodies in systemic lupus erythematosus: Clinical and laboratory correlations. The American Journal of Medicine, 99, 624–8.Google Scholar

Ainiala, H. et al., 2001. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology, 57, 496–500.Google Scholar

Appenzeller, S. et al., 2008. Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Annals of Neurology, 64, 635–43.Google Scholar

Arnaud, L. et al., 2014. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis. Autoimmunity Reviews, 13, 281–91.Google Scholar

Asanuma, Y. et al., 2003. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. New England Journal of Medicine, 349, 2407–15.CrossRefGoogle ScholarPubMed

Aviña-Zubieta, J. A. et al., 2015. The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: A general population-based study. Seminars in Arthritis and Rheumatism, 45, 195–201.Google Scholar

Azarpazhooh, M. R. et al., 2010. Microembolic signals in patients with systemic lupus erythematosus. The Canadian Journal of Neurological Sciences, 37, 371–5.Google Scholar

Baizabal-Carvallo, J. F. & Samson, Y., 2010. Microembolic signals in systemic lupus erythematosus and other cerebral small vessel diseases. Journal of Neurology, 257, 503–8.Google Scholar

Brey, R. L. et al., 2002. Neuropsychiatric syndromes in lupus: Prevalence using standardized definitions. Neurology, 58, 1214–20.Google Scholar

Bruce, I. N., 2005. “Not only … but also”: Factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology, 44, 1492–1502.Google Scholar

Cantú-Brito, C. et al., 2010. The clinical significance of microembolic signals in patients with systemic lupus erythematosus. Neurological Research, 32, 134–8.Google Scholar

Cervera, R. et al., 2003. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine, 82, 299–308.Google Scholar

D’Cruz, D. P., Khamashta, M. A., & Hughes, G. R. V., 2007. Systemic lupus erythematosus. Lancet, 369, 587–96.Google Scholar

Dahl, A. et al., 2006. Detection of cerebral embolic signals in patients with systemic lupus erythematosus. Journal of Neurology, Neurosurgery, and Psychiatry, 77, 774–9.Google Scholar

Danchenko, N., Satia, J., & Anthony, M. S., 2006. Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden. Lupus, 15, 308–18.Google Scholar

Devinsky, O., Petito, C. K., & Alonso, D. R., 1988. Clinical and neuropathological findings in systemic lupus erythematosus: The role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Annals of Neurology, 23, 380–4.Google Scholar

Ellis, S. G. & Verity, M. A., 1979. Central nervous system involvement in systemic lupus erythematosus: A review of neuropathologic findings in 57 cases, 1955–1977. Seminars in Arthritis and Rheumatism, 8, 212–21.Google Scholar

Erkan, D. et al., 2007. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum, 56, 2382–91.Google Scholar

Fernández-Nebro, A. et al., 2015. Cardiovascular events in systemic lupus erythematosus. Medicine, 94, e1183.Google Scholar

Fox, I. S. et al., 1980. Cerebral embolism in Libman–Sacks endocarditis. Neurology, 30, 487–91.Google Scholar

Goel, D. et al., 2007. Active necrotizing cerebral vasculitis in systemic lupus erythematosus. Neuropathology, 27, 561–5.Google Scholar

Hochberg, M., 1997. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism, 40, 1997.Google Scholar

Jauch, E. C. et al., 2013. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 44, 870–947.Google Scholar

Johnson, R. T. & Richardson, E. P., 1968. The neurological manifestations of systemic lupus erythematosus. Medicine, 47, 337–69.Google Scholar

Kernan, W. N. et al., 2014. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 45, 2160–236.Google Scholar

Kitagawa, Y. et al., 1990. Stroke in systemic lupus erythematosus. Stroke, 21, 1533–9.Google Scholar

Krishnan, E., 2005. Stroke subtypes among young patients with systemic lupus erythematosus. The American Journal of Medicine, 118, 1415.Google Scholar

Libman, E. & Sacks, B., 1924. A hitherto undescribed form of valvular and mural endocarditis. Archives of Internal Medicine, 33, 701–37.Google Scholar

Mimori, A. et al., 2000. Subarachnoid hemorrhage and systemic lupus erythematosus. Lupus, 9, 521–6.CrossRefGoogle ScholarPubMed

Moyssakis, I. et al., 2007. Libman–Sacks endocarditis in systemic lupus erythematosus: Prevalence, associations, and evolution. The American Journal of Medicine, 120, 636–42.Google Scholar

Osler, W., 1904. On the visceral manifestations of the erythema group of skin diseases. The American Journal of the Medical Sciences, 127, 1–23.Google Scholar

Osler, W., 1900. The visceral lesions of the erythema group. The British Journal of Dermatology, 12, 227–45.Google Scholar

Petri, M. A. et al., 2011. Lupus Atherosclerosis Prevention Study (LAPS). Annals of the Rheumatic Diseases, 70, 760–5.Google Scholar

Ramos-Casals, M. et al., 2006. Vasculitis in systemic lupus erythematosus: Prevalence and clinical characteristics in 670 patients. Medicine, 85, 95–104.Google Scholar

Roldan, C. A. et al., 2013. Libman–Sacks endocarditis and embolic cerebrovascular disease. JACC. Cardiovascular Imaging, 6, 973–83.Google Scholar

Roldan, C. A. et al., 2008. Transthoracic versus transesophageal echocardiography for detection of Libman–Sacks endocarditis: A randomized controlled study. Journal of Rheumatology, 35, 224–9.Google Scholar

Roman, M. J. et al., 2003. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. New England Journal of Medicine, 349, 2399–406.Google Scholar

Sarbu, N. et al., 2015. Brain abnormalities in newly diagnosed neuropsychiatric lupus: Systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmunity Reviews, 14, 153–9.Google Scholar

Schoenfeld, S. R., Kasturi, S., & Costenbader, K. H., 2013. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: A systematic review. Seminars in Arthritis and Rheumatism, 43, 77–95.Google Scholar

Sibbitt, W. L. et al., 2010. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 40, 32–52.Google Scholar

Soubrier, M. et al., 2013. Do all lupus patients need statins? Joint, Bone, Spine: Revue du Rhumatisme, 80, 244–9.Google Scholar

Suzuki, Y. et al., 1990. Severe cerebral and systemic necrotizing vasculitis developing during pregnancy in a case of systemic lupus erythematosus. Journal of Rheumatology, 17, 1408–11.Google Scholar

Timlin, H. & Petri, M., 2013. Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus, 22, 1251–8.Google Scholar

Wang, L. et al., 2015. Clinical characteristics of cerebral venous sinus thrombosis in patients with systemic lupus erythematosus: A single-centre experience in China. Journal of Immunology Research, 2015, 1–7.Google Scholar

Adams, HP Jr. Cerebral vasculitis. Handb Clin Neurol. 2014;119:475–94.Google Scholar

Behrouz, R. The risk of ischemic stroke in major rheumatic disorders. J Neuroimmunol. 2014;277:1–5.Google Scholar

Jastrzebska, M, Czok, ME, Guzik, P. Autoimmune diseases, their pharmacological treatment and the cardiovascular system. Cardiol J. 2013;20:569–76.Google Scholar

Sanna, G, Bertolaccini, ML, Cuadrado, MJ, Khamashta, MA, Hughes, GRV. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology. 2003;42:200–13.Google Scholar

Dafer, RM, Biller, J. Antiphospholipid syndrome: Role of antiphospholipid antibodies in neurology. Hematol Oncol Clin N Am. 2008;22:95–105.Google Scholar

Miyakis, S, Locksin, MD, Atsumi, T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.Google Scholar

Kim, JH, Choi, CG, Choi, SJ, Lee, HK, Suh, DC. Primary antiphospholipid antibody syndrome: Neuroradiologic findings in 11 patients. Korean J Radiol. 2000;1:5–10.Google Scholar

Muscal, E, Brey, RL. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus. 2010;19:406–11.Google Scholar

Levine, SR, Deegan, MJ, Futrell, N, Welch, KMA. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology. 1990;40:1181–9.Google Scholar

Rodrigues, CEM, Carvalho, JF, Shoenfeld, Y. Neurological manifestations of antiphospholipid syndrome. Eur J Clin Invest. 2010;40:350–9.Google Scholar

Gomez-Puerta, JA, Cervera, R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun. 2014;48–49:20–5.Google Scholar

Brey, RL. Antiphospholipid antibodies in young adults with stroke. J Thromb Thrombolysis. 2005;20:105–12.Google Scholar

Tuhrim, S. Antiphospholipid antibodies and stroke. Curr Cardiol Rep. 2004;6:130–4.Google Scholar

Brey, RL, Chapman, J, Levine, SR, et al. Stroke and the antiphospholipid syndrome: Consensus meeting Taormina 2002. Lupus. 2003;23:508–13.Google Scholar

Muscal, E, Brey, RL. Neurological manifestations of the antiphospholipid syndrome: Risk assessments and evidence-based medicine. Int J Clin Pract. 2007;61:1561–8.Google Scholar

Ruiz-Irastorza, G, Hunt, BJ, Khamashta, MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;15:1487–95.Google Scholar

Mineo, C. Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis. Curr Rheumatol Rep. 2013;15(5):324.Google Scholar

Ortel, TL. The antiphospholipid syndrome: What are we really measuring? How do we measure it? And how do we treat it? J Thromb Thrombolysis. 2006;21:79–83.Google Scholar

Jara, LJ, Medina, G, Vera-Lastra, O. Systemic antiphospholipid syndrome and atherosclerosis. Clinic Rev Allerg Immunol. 2007;32:172–7.Google Scholar

Kluger, BM, Hughes, RL, Anderson, CA, Hassell, KL. Non-traumatic carotid dissection and stroke associated with anti-phospholipid antibody syndrome: Report of a case and review of the literature. Neurol India. 2008;56:77–8.Google Scholar

Merrill, JT. Antiphospholipid syndrome: What’s new in understanding antiphospholipid antibody-related stroke? Curr Rheumatol Rep. 2006;8:159–61.Google Scholar

Lee, JL, Naguwa, SM, Cheema, GS, Gershwin, ME. Revisiting Libman–Sacks endocarditis: A historical review and update. Clin Rev Allergy Immunol. 2009;36:126–30.Google Scholar

Specker, C, Pernoik, A, Brauckmann, U, Siebler, M, Schneider, M. Detection of cerebral microemboli in APS: Introducing a novel investigation method and implications of analogies with carotid artery disease. Lupus. 1998;7 Suppl 2:S75–80.Google Scholar

Moll, S, McCloud, M, Ortel, TL. Subdural hematoma and lupus anticoagulants. Stroke. 1997;28:646–8.Google Scholar

Carangelo, B, Peri, G, Signori, G, Palma, L. Chronic hemispheric subdural hematoma in a patient with antiphospholipid antibody syndrome: Case report. J Neurosurg Sci. 2009;53:141–3.Google Scholar

Ruiz-Irastorza, G, Khamashta, MA, Hunt, BJ, Escudero, A, Cuadrado, MJ, Hughes, GR. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: Analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med. 2002;162:1164–9.Google Scholar

Carecchio, M, Cantello, R, Comi, C. Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: Beyond vascular damage. J Immunol Res. 2014;2014:239398.Google Scholar

Cervera, R, Boffa, MC, Khamashta, MA, Hughes, GR. The Euro-Phospholipid Project: Epidemiology of the antiphospholipid syndrome in Europe. Lupus. 2009;18:889–93.Google Scholar

Carhuapoma, JR, Mitsias, P, Levine, SR. Cerebral venous thrombosis and anticardiolipin antibodies. Stroke. 1997;28:2363–9.Google Scholar

Gezer, S. Antiphospholipid syndrome. Dis Mon. 2003;49:691–741.Google Scholar

Asherson, RA, Cervera, R, de Groot, PG, et al. Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530–534.Google Scholar

Bucciarelli, S, Cervera, R, Espinosa, G, et al. Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors. Autoimmun Rev. 2006;6:72–5.Google Scholar

Erkan, D, Harrison, MJ, Levy, R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56:2382–91.Google Scholar

Ruiz-Irastorza, G, Cuadrado, MJ, Ruiz-Arruza, I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies. Lupus. 2011;20:206–18.Google Scholar

Levine, SR, Brey, RL, Tilley, BC et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576–84.Google Scholar

Panichpisal, K, Rozner, E, Levine, SR. The management of stroke in antiphospholipid syndrome. Curr Rheumatol Rep. 2012;14:99–105.Google Scholar

Erkan, D, Vega, J, Ramon, G, Kozora, E, Lockshin, MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65:464–71.Google Scholar

Cuadrado, MJ. Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome). Curr Rheumatol Rep. 2002;4:392–8.Google Scholar

Cohen, H, Machin, SJ. Antithrombotic treatment failures in antiphospholipid syndrome: The new anticoagulants? Lupus. 2010;19:486–91.Google Scholar

Peixoto, MV, de Carvalho, JF, Rodrigues, CE. Clinical, laboratory, and therapeutic analysis of 21 patients with neonatal thrombosis and antiphospholipid antibodies: A literature review. J Immunol Res. 2014;2014:672603.Google Scholar

Lundstrom, E, Gustafsson, JT, Jonsen, A, et al. HLA-DRB*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis. 2013;72:1018–25.Google Scholar

Hochberg, MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum. 1997;40:1725.Google Scholar

ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608.Google Scholar

Van Dam, AP. Diagnosis and pathogenesis of CNS lupus. Rheumatol Int. 1991;11:1–11.Google Scholar

Sibbitt, WL Jr, Sibbitt, RR, Brooks, WM. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1999;42:2026–38.Google Scholar

Timlin, H, Petri, M. Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus. 2013;22:1251–8.Google Scholar

Wierzbicki, AS. Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus. Lupus. 2000;9:194–201.Google Scholar

Jennekens, FG, Kater, L. The central nervous system in systemic lupus erythematous. Part 2. Pathogenetic mechanisms of clinical syndromes: A literature investigation. Rheumatology (Oxford). 2002;41:619–30.Google Scholar

Mitsias, P, Levine, SR. Large cerebral vessel occlusive disease in systemic lupus erythematosus. Neurology. 1994;44:385–93.Google Scholar

Wang, R, Xu, Y, Lv, R, Chen, J. Systemic lupus erythematosus associated with moyamoya syndrome: A case report and literature review. Lupus. 2013;22:629–33.Google Scholar

Owada, T, Takahashi, K, Kita, Y. Subarachnoid hemorrhage in systemic lupus erythematosus in Japan: Two case reports and a review of the literature. Mod Rheumatol. 2009;19:573–80.Google Scholar

Nakai, Y, Hyodo, A, Yanaka, K, Akutsu, H, Nose, T. Distal superior cerebellar artery aneurysm in a patient with systemic lupus erythematosus: Case report. Surg Neurol. 2000;54:73–6.Google Scholar

Laversuch, CJ, Brown, MM, Clifton, A, Bourke, BE. Cerebral venous thrombosis and acquired protein S deficiency: An uncommon cause of headache in systemic lupus erythematosus. Br J Rheumatol. 1995;34:572–5.Google Scholar

Uthman, I, Khalil, I, Sawaya, R, Taher, A. Lupus anticoagulant, factor V Leiden, and methylenetetrahydrofolate reductase gene mutation in a lupus patient with cerebral venous thrombosis. Clin Rheumatol. 2004;23:362–3.Google Scholar

Alboudi, A, Sarathchandran, P, Alrukn, S, Al Madani, A. Cerebral venous thrombosis presenting with subdural haematoma as first presentation for systemic lupus erythematosus with negative antiphospholipid antibodies. BMJ Case Rep. 2014: doi: 10.1136/bcr-2014-205355.Google Scholar

Broussalis, E, Trinka, E, Kraus, J, McCoy, M, Killer, M. Treatment strategies for vasculitis that affects the nervous system. Drug Discov Today. 2013;18:818–35.Google Scholar

Yu, HH, Lee, JH, Wang, LC, Yang, YH, Chiang, BL. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: A 20-year study. Lupus. 2006;15:651–7.Google Scholar

Levy, DM, Massicotte, MP, Harvey, E, Hebert, D, Silverman, ED. Thromboembolism in paediatric lupus patients. Lupus. 2003;12:741–6.Google Scholar

Saini, AG, Sankhyan, N, Bhattad, S, et al. CNS vasculitis and stroke in neonatal lupus erythematosus: A case report and review of literature. Eur J Paediatr Neurol. 2014;18:444–8.Google Scholar

Shiboski, CH, Shiboski, SC, Seror, R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69:35–45.Google Scholar

Niemela, RA, Hakala, M. Primary Sjögren’s syndrome with severe central nervous system disease. Semin Arthritis Rheum. 1999;29:4–13.Google Scholar

Segal, B, Carpenter, A, Walk, D. Involvement of nervous system pathways in primary Sjögren’s syndrome. Rheum Dis Clin N Am. 2008;34:885–906.Google Scholar

Simmons-O’Brien, E, Chen, S, Watson, R, et al. One hundred anti-Ro (SS-A) antibody positive patients: A 10-year follow-up. Medicine (Baltimore). 1995;74:109–30.Google Scholar

Ishizaka, S, Hayashi, K, Otsuka, M, et al. Syringomelia and arachnoid cysts associated with spinal arachnoiditis following subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 2012;52:686–90.Google Scholar

Marinos, G, Riley, J, Painter, DM, McCaughan, GW. Sulfasalazine-induced fulminant hepatic failure. J Clin Gastroenterol. 1992;14:132–5.Google Scholar

Urban, E, Jabbari, B, Robles, H. Concurrent cerebral venous sinus thrombosis and myeloradiculopathy in Sjögren’s syndrome. Neurology. 1994;44:554–6.Google Scholar

Delalande, S, de Seze, J, Fauchais, AL, et al. Neurologic manifestations in primary Sjögren syndrome: A study of 82 patients. Medicine (Baltimore). 2004;83:280–91.Google Scholar

Saip, S, Skman-Demir, G, Siva, A. Neuro-Behçet syndrome. Handb Clin Neurol. 2014;121:1703–23.Google Scholar

International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–80.Google Scholar

Siva, A, Saip, S. The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis. J Neurol. 2009;156:513–29.Google Scholar

Kikuchi, S, Niino, M, Shinpo, K, Terae, S, Tashiro, K. Intracranial hemorrhage in neuro-Behçet’s syndrome. Intern Med. 2002;41:692–5.Google Scholar

Kocak, A, Cayli, SR, Ates, O, Sarac, K. Middle cerebral artery aneurysm associated with Behçet’s disease. Neurol Med Chir (Tokyo). 2004;44:368–71.Google Scholar

Ho, CL, Deruytter, MJ. Manifestations of neuro-Behçet’s disease. Report of two cases and review of the literature. Clin Neurol Neurosurg. 2005;107:310–14.Google Scholar

Aguiar de Sousa, D, Mestre, T, Ferro, JM. Cerebral venous thrombosis in Behçet’s disease: A systematic review. J Neurol. 2011;258:719–27.Google Scholar

Iannetti, L, Zito, R, Bruschi, S, et al. Recent understanding on diagnosis and management of central nervous system vasculitis in children. Clin Dev Immunol. 2012;2012:698327.Google Scholar

Zaiden, M, Mariotte, E, Galicier, L, et al. Vasculitic emergencies in the intensive care unit: A special focus on cryoglobulinemic vasculitis. Ann Intensive Care. 2012;2:31.Google Scholar

De Vita, S, Soldano, F, Isola, M, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis. 2011;70:1183–90.Google Scholar

Ghetie, D, Mehraban, N, Sibley, CH. Cold hard facts of cryoglobulinemia: Updates on clinical features and treatment advances. Rheum Dis Clin North Am. 2015;41:93–108.Google Scholar

Mazzola, L, Antoine, JC, Camdessanche, JP, et al. Brain hemorrhage as a complication of type I cryoglobulinemia vasculopathy. J Neurol. 2003;250:1376–8.Google Scholar

Adinolfi, LE, Zampino, R, Restivo, L, et al. Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. World J Gastroenterol. 2014;20:3410–17.Google Scholar

Ramos-Casals, M, Robles, A, Brito-Zeron, P, et al. Life-threatening cryoglobulinemia: Clinical and immunological characterization of 29 cases. Semin Arthritis Rheum. 2006;36:189–96.Google Scholar

Holle, JU, Gross, WL. Neurological involvement in Wegener’s granulomatosis. Curr Opin Rheumatol. 2011;23:7–11.Google Scholar

American College of Rheumatology. 1990 Criteria for the classification of Wegener’s granulomatosis (now known as granulomatosis with polyangiitis). http://www.rheumatology.org/Practice-Quality/Clinical-Support/Criteria/ACR-Endorsed-Criteria. Accessed 28 November 2015.Google Scholar

de Leeuw, K, Sanders, JS, Stegeman, C, et al. Accelerated atherosclerosis in patients with Wegener’s granulomatosis. Ann Rheum Dis. 2005;64:753–9.Google Scholar

Davison, R, Sheerin, NS. Granulomatosis with polyangiitis presenting as ischaemic stroke. JRSM Short Rep. 2012;3:81.Google Scholar

Nowack, R, Wachtler, P, Kunz, J, Rasmussen, N. Cranial nerve palsy in Wegener’s granulomatosis: Lessons from clinical cases. J Neurol. 2009;256:299–304.Google Scholar

Nesher, G. The diagnosis and classification of giant cell arteritis. J Autoimmun. 2014;48–49:73–5.Google Scholar

Chatterjee, S, Flamm, SD, Tan, CD, Rodriguez, ER. Clinical diagnosis and management of large vessel vasculitis: Giant cell arteritis. Curr Cardiol Rep. 2014;16:498.Google Scholar

Ness, T, Bley, TA, Schmidt, WA, Lamprecht, P. The diagnosis and treatment of giant cell arteritis. Dtsch Arztebl Int. 2013;110:376–85.Google Scholar

Weyand, CM, Goronzy, JJ. Giant-cell arteritis and polymyalgia rheumatic. N Engl J Med. 2014;371:50–7.Google Scholar

American College of Rheumatology. 1990 Criteria for the classification of giant cell (temporal) arteritis – excerpt. http://www.rheumatology.org/Practice-Quality/Clinical-Support/Criteria/ACR-Endorsed-Criteria. Accessed 28 November 2015.Google Scholar

Mollan, SP, Sharrack, N, Burdon, MA, Denniston, AK. Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst Rev. 2014;8:CD010453.Google Scholar

Caylor, TL, Perkins, A. Recognition and management of polymyalgia rheumatica and giant cell arteritis. Am Fam Physician. 2013;88:676–84.Google Scholar

Smith, JH, Swanson, JW. Giant cell arteritis. Headache. 2014;54:1273–89.Google Scholar

Mahr, AD, Jover, JA, Spiera, RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. Arthritis Rheum. 2007;86:2789–97.Google Scholar

Martinez-Taboada, VM, Lopez-Hoyos, M, Narvaez, J, Munoz-Cacho, P. Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: A cumulative meta-analysis. Autoimmun Rev. 2014;13:788–94.Google Scholar

Gupta, V, Chinchure, SD, Goel, G, et al. Coil embolization of intracranial aneurysm in polyarteritis nodosa. A case report and review of the literature. Interv Neuroradiol. 2013;19:203–8.Google Scholar

American College of Rheumatology. 1990 Criteria for the Classification of polyarteritis nodosa. http://www.rheumatology.org/Practice-Quality/Clinical-Support/Criteria/ACR-Endorsed-Criteria. Accessed 28 November 2015.Google Scholar

Pagnoux, C, Seror, R, Henegar, C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62:6116–26.Google Scholar

Reichart, MD, Bogousslavsky, J, Janzer, RC. Early lacunar strokes complicating polyarteritis nodosa: Thrombotic microangiopathy. Neurology. 2000;54:883–9.Google Scholar

Provenzale, JM, Allen, NB. Neuroradiologic findings in polyarteritis nodosa. AJNR Am J Neuroradiol. 1996;17:1119–26.Google Scholar

Ford, RG, Siekert, RG. Central nervous system manifestations of periarteritis nodosa. Neurology. 1965;15:114–22.Google Scholar

Hajj-Ali, RA, Calabrese, LH. Diagnosis and classification of central nervous system vasculitis. J Autoimmun. 2014;48–49:149–52.Google Scholar

Calabrese, LH, Mallek, JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic critera. Medicine (Baltimore). 1988;67:20–39.Google Scholar

Birnbaum, J, Hellmann, DB. Primary angiitis of the central nervous system. Arch Neurol. 2009;66:704–9.Google Scholar

Berlit, P, Kraemer, M. Cerebral vasculitis in adults: What are the steps in order to establish the diagnosis? Red flags and pitfalls. Clin Exp Immunol. 2013;175:419–24.Google Scholar

Lucke, M, Hajj-Ali, RA. Advances in primary angiitis of the central nervous system. Curr Cardiol Rep. 2014;16:533.Google Scholar

Suri, V, Kakkar, A, Sharma, MC, et al. Primary angiitis of the central nervous system: A study of histopathological patterns and review of the literature. Folia Neuropathol. 2014;52:187–96.Google Scholar

Merkel, PA, Koroshetz, WJ, Irizarry, MC, Cudkowicz, ME. Cocaine-associated cerebral vasculitis. Semin Arthritis Rheum. 1995;25:172–83.Google Scholar

Hajj-Ali, RA, Calabrese, LH. Primary angiitis of the central nervous system. Autoimmunity Reviews. 2013;12:463–6.Google Scholar

Nogueras, C, Sala, M, Sasal, M, et al. Recurrent stroke as a manifestation of primary angiitis of the central nervous system in a patient infected with human immunodeficiency virus. Arch Neurol. 2002;59:468–73.Google Scholar

Yasuda, Y, Matsuda, I, Kang, Y, Saiga, T, Kameyama, M. Isolated angiitis of the central nervous system first presenting as intracranial hemorrhage during cesarean section. Intern Med. 1993;32:745–8.Google Scholar

Biller, J, Loftus, CM, Moore, SA, et al. Isolated central nervous system angiitis first presenting as spontaneous intracranial hemorrhage. Neurosurgery. 1987;20:310–15.Google Scholar

Ozawa, T, Sasaki, O, Sorimachi, T, Tanaka, R. Primary angiitis of the central nervous system: Report of two cases and review of the literature. Neurosurgery. 1995;36:173–9.Google Scholar

Twilt, M, Benseler, SM. The spectrum of CNS vasculitis in children and adults. Nat Rev Rheumatol. 2012;8:97–107.Google Scholar

Gowdie, P, Twilt, M, Benseler, SM. Primary and secondary central nervous system vasculitis. J Child Neurol. 2012;27:1448–59.Google Scholar

Park, MS, Marlin, AE, Gaskill, SJ. Angiography-negative primary angiitis of the central nervous system in childhood. J Neurosurg Pediatr. 2014;13:62–7.Google Scholar

Cellucci, T, Benseler, SM. Central nervous system vasculitis in children. Curr Opin Rheumatol. 2010;22:590–7.Google Scholar

Pistracher, K, Gellner, V, Riegler, S, et al. Cerebral haemorrhage in the presence of primary childhood central nervous system vasculitis: A review. Childs Nerv Syst. 2012;28:1141–8.Google Scholar

Hutchinson, C, Elbers, J, Halliday, W, et al. Treatment of small vessel primary CNS vasculitis in children: An open-label cohort study. Lancet Neurol. 2010;9:1078–84.Google Scholar

Aletaha, D, Neogi, T, Silman, AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81.Google Scholar

Meune, C, Touze, E, Trinquart, L, Allanore, Y. High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis. 2010;103:253–61.Google Scholar

Kitas, GD, Gabriel, SE. Cardiovascular disease in rheumatoid arthritis: State of the art and future perspectives. Ann Rheum Dis. 2011;70:8–14.Google Scholar

Dhawan, SS, Quyyumi, AA. Rheumatoid arthritis and cardiovascular disease. Curr Atheroscler Rep. 2008;10:128–33.Google Scholar

Ruyssen-Weitrand, A, Fautrel, B, Saraux, A, Loet, XL, Pham, T. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: A systematic literature review. Joint Bone Spine. 2011;78:23–30.Google Scholar

Ohno, T, Matsuda, I, Furukawa, H, Kanoh, T. Recovery from rheumatoid cerebral vasculitis by low-dose methotrexate. Internal Medicine. 1994;33:615–20.Google Scholar

De Carvalho, M, Swash, M. Neurologic complications of craniovertebral dislocation. Handb Clin Neurol. 2014;119:435–48.Google Scholar

Mills, JA, Michel, BA, Bloch, DA, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum. 1990;33:1114–21.Google Scholar

Berube, MD, Blais, N, Lanthier, S. Neurologic manifestations of Henoch–Schönlein purpura. Handb Clin Neurol. 2014;120:1101–11.Google Scholar

van den Hoogen, F, Khanna, D, Fransen, J, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737–47.Google Scholar

Amaral, TN, Peres, FA, Lapa, AT, Marques-Neto, JF, Appenzeller, S. Neurologic involvement in scleroderma: A systematic review. Semin Arthritis Rheumatism. 2013;43:335–47.Google Scholar

Das, CP, Rabhakar, S, Lal, V, Kharbanda, PS. Scleroderma, stroke, optic neuropathy: A rare association. Neurol India. 2002;50:504–7.Google Scholar

Smith, JA. Update on ankylosing spondylitis: Current concepts in pathogenesis. Curr Allergy Asthma Rep. 2015;15:489.Google Scholar

van Tubergen, A, Weber, U. Diagnosis and classification in spondyloarthritis: Identifying a chameleon. Nat Rev Rheumatol. 2012;8:253–61.Google Scholar

van der Linden, S, Valkenburg, HA, Cats, A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8.Google Scholar

Mathieu, S, Gossec, L, Dougados, M, Soubrier, M. Cardiovascular profile in ankylosing spondylitis: A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63:557–63.Google Scholar

Kaprove, RE, Little, AH, Graham, DC, Rosen, PS. Ankylosing spondylitis: Survival in men with and without radiotherapy. Arthritis Rheum. 1980;23:57–61.Google Scholar

Dutra, LA, Braga-Neto, P, Pedroso, JL, Barsottini, OG. Sneddon’s syndrome: Case report and review of its relationship with antiphospholipid syndrome. Einstein (Sao Paulo). 2012;10:230–2.Google Scholar

Bolayir, E, Yilmaz, A, Kugu, N, Erdogan, H, Akyol, M, Akyuz, A. Sneddon’s syndrome: Clinical and laboratory analysis of 10 cases. Acta Med Okayama. 2004;58:59–95.Google Scholar

Wu, S, Xu, Z, Liang, H. Sneddon’s syndrome: A comprehensive review of the literature. Orphanet J Rare Dis. 2014;9:215.Google Scholar

Rebollo, M, Val, JF, Garijo, F, Quintana, F, Berciano, J. Livedo reticularis and cerebrovascular lesions (Sneddon’s syndrome). Clinical, radiological and pathological features in eight cases. Brain. 1983;106:965–79.Google Scholar

Wu, W, Chaer, RA. Nonarteriosclerotic vascular disease. Surg Clin North Am. 2013;93:833–75.Google Scholar

American College of Rheumatology. 1990 criteria for the classification of Takayasu arteritis. http://www.rheumatology.org/Practice-Quality/Clinical-Support/Criteria/ACR-Endorsed-Criteria. Accessed 28 November 2015.Google Scholar

Chatterjee, S, Flamm, SD, Tan, CD, Rodriguez, ER. Clinical diagnosis and management of large vessel vasculitis: Takayasu arteritis. Curr Cardiol Rep. 2014;16:499.Google Scholar

American College of Rheumatology. 1990 criteria for the classification of Churg-Strauss syndomre (traditional format), their sensitivity and specificity versus other defined vasculitis syndromes. http://www.rheumatology.org/Practice-Quality/Clinical-Support/Criteria/ACR-Endorsed-Criteria. Accessed 28 November 2015.Google Scholar

Burns, JC, Glode, MP. Kawasaki syndrome. Lancet. 2004;364:533–44.Google Scholar

Chowdhury, SR, Majumder, S, Chakraborty, PP, et al. Headache in a case of Rhupus syndrome. Headache. 2008;48:155–8.Google Scholar

Adams, B. D. et al., 2010. Myeloproliferative disorders and the hyperviscosity syndrome. Hematology/Oncology Clinics of North America, 24, 585–602. Available at: www.ncbi.nlm.nih.gov/pubmed/20488356 [Accessed December 15, 2015].Google Scholar

Alexandrescu, D. T. et al., 2005. Strokes after intravenous gamma globulin: Thrombotic phenomenon in patients with risk factors or just coincidence? American Journal of Hematology, 78, 216–20. Available at: www.ncbi.nlm.nih.gov/pubmed/15726606 [Accessed November 19, 2015].Google Scholar

Allport, L. E. et al., 2005. Elevated hematocrit is associated with reduced reperfusion and tissue survival in acute stroke. Neurology, 65, 1382–7. Available at: www.ncbi.nlm.nih.gov/pubmed/16275824 [Accessed December 15, 2015].Google Scholar

Anon, 1975. Editorial: Haemorheology, blood-flow and venous thrombosis. Lancet, 2, 113–4. Available at: www.ncbi.nlm.nih.gov/pubmed/49700 [Accessed November 22, 2015].Google Scholar

Artoni, A., Bucciarelli, P., & Martinelli, I., 2014. Cerebral thrombosis and myeloproliferative neoplasms. Current Neurology and Neuroscience Reports, 14, 496. Available at: www.ncbi.nlm.nih.gov/pubmed/25217248 [Accessed December 6, 2015].Google Scholar

Baker, I. A. et al., 2002. Fibrinogen, viscosity and white blood cell count predict myocardial, but not cerebral infarction: Evidence from the Caerphilly and Speedwell cohort. Thrombosis and Haemostasis, 87, 421–5. Available at: www.ncbi.nlm.nih.gov/pubmed/11916073 [Accessed November 15, 2015].Google Scholar

Barabas, A. P., Offen, D. N., & Meinhard, E. A., 1973. The arterial complications of polycythaemia vera. British Journal of Surgery, 60, 183–7. Available at: www.ncbi.nlm.nih.gov/pubmed/4693567 [Accessed November 20, 2015].Google Scholar

Berk, P. D. et al., 1986. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Seminars in Hematology, 23, 132–43. Available at: www.ncbi.nlm.nih.gov/pubmed/3704665 [Accessed November 20, 2015].Google Scholar

Billakota, S. & El Husseini, N., 2014. Pearls & oysters: Polycythemia vera presenting with ischemic strokes in multiple arterial territories. Neurology, 82, e168–70. Available at: www.ncbi.nlm.nih.gov/pubmed/24843039 [Accessed December 15, 2015].Google Scholar

Boulanger, E. et al., 2006. Polyclonal IgG4 hypergammaglobulinemia associated with plasmacytic lymphadenopathy, anemia and nephropathy. Annals of Hematology, 85, 833–40. Available at: www.ncbi.nlm.nih.gov/pubmed/16871390 [Accessed December 15, 2015].Google Scholar

Bunn, H. F., 1997. Pathogenesis and treatment of sickle cell disease. New England Journal of Medicine, 337, 762–9. Available at: www.ncbi.nlm.nih.gov/pubmed/9287233 [Accessed November 20, 2015].Google Scholar

Byrne, N.P. et al., 2002. Neuropathologic findings in a Guillain–Barré patient with strokes after IVIg therapy. Neurology, 59, 458–61. Available at: www.ncbi.nlm.nih.gov/pubmed/12177388 [Accessed November 20, 2015].Google Scholar

Caplan, L.R., 1995. Binswanger’s disease: Revisited. Neurology, 45, 626–33.Google Scholar

Caress, J. B. et al., 2003. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology, 60, 1822–4. Available at: www.ncbi.nlm.nih.gov/pubmed/12796539 [Accessed November 22, 2015].Google Scholar

Caress, J. B. et al., 2009. Case–control study of thromboembolic events associated with IV immunoglobulin. Journal of Neurology, 256, 339–42. Available at: www.ncbi.nlm.nih.gov/pubmed/19253011 [Accessed December 7, 2015].Google Scholar

Chang, T. et al., 2014. Cerebral infarction 3 weeks after intravenous immunoglobulin for Miller Fisher syndrome: A case report. Journal of Medical Case Reports, 8, 100. Available at: www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4007143&tool=pmcentrez&rendertype=abstract [Accessed December 15, 2015].Google Scholar

Chang, T. S. & Jensen, M. B., 2014. Haemodilution for acute ischaemic stroke. The Cochrane Database of Systematic Reviews, 8, CD000103. Available at: www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4181849&tool=pmcentrez&rendertype=abstract [Accessed November 25, 2015].Google Scholar

Chen, L. Y. et al., 2015. Polyclonal hyperviscosity syndrome in IgG4-related disease and associated conditions. Clinical Case Reports, 3, 217–26.Google Scholar

Chien, S., Usami, S., & Bertles, J. F., 1970. Abnormal rheology of oxygenated blood in sickle cell anemia. Journal of Clinical Investigation, 49, 623–34. Available at: www.pubmedcentral.nih.gov/articlerender.fcgi?artid=322516&tool=pmcentrez&rendertype=abstract [Accessed October 20, 2015].Google Scholar

Choi, W.-J. et al., 2012. Acute cerebellar infarction associated with intravenous gammaglobulin treatment in idiopathic thrombocytopenic purpura. Journal of Stroke and Cerebrovascular Diseases, 21, e9–11. Available at: www.ncbi.nlm.nih.gov/pubmed/22749629 [Accessed December 15, 2015].Google Scholar

Connes, P., Verlhac, S., & Bernaudin, F., 2013. Advances in understanding the pathogenesis of cerebrovascular vasculopathy in sickle cell anaemia. British Journal of Haematology, 161, 484–98. Available at: www.ncbi.nlm.nih.gov/pubmed/23496688 [Accessed December 15, 2015].Google Scholar

Coull, B. M. et al., 1991. Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke, 22, 162–8. Available at: www.ncbi.nlm.nih.gov/pubmed/2003279 [Accessed November 22, 2015].Google Scholar

Cowan, A. Q., Cho, D. J., & Rosenson, R. S., 2012. Importance of blood rheology in the pathophysiology of atherothrombosis. Cardiovascular Drugs and Therapy, 26, 339–48. Available at: www.ncbi.nlm.nih.gov/pubmed/22821616 [Accessed December 6, 2015].Google Scholar

Danesh, J. et al., 2005. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. JAMA, 294, 1799–809. Available at: www.ncbi.nlm.nih.gov/pubmed/16219884 [Accessed November 22, 2015].Google Scholar

Davalos, D. & Akassoglou, K., 2012. Fibrinogen as a key regulator of inflammation in disease. Seminars in Immunopathology, 34, 43–62. Available at: www.ncbi.nlm.nih.gov/pubmed/22037947 [Accessed November 13, 2015].Google Scholar

Dintenfass, L., 1966. A preliminary outline of the blood high viscosity syndromes. Archives of Internal Medicine, 118, 427–35. Available at: www.ncbi.nlm.nih.gov/pubmed/5332028 [Accessed November 22, 2015].Google Scholar

Dintenfass, L., 1968. Internal viscosity of the red cell and a blood viscosity equation. Nature, 219, 956–8. Available at: www.ncbi.nlm.nih.gov/pubmed/5673017 [Accessed November 19, 2015].Google Scholar

Dormandy, J. A., Yates, C. J., & Berent, G. A., 1981. Clinical relevance of blood viscosity and red cell deformability including newer therapeutic aspects. Angiology, 32, 236–42. Available at: www.ncbi.nlm.nih.gov/pubmed/7224233 [Accessed November 22, 2015].Google Scholar

Emerson, G. G., Herndon, C. N., & Sreih, A. G., 2002. Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy, 22, 1638–41. Available at: www.ncbi.nlm.nih.gov/pubmed/12495174 [Accessed November 22, 2015].Google Scholar

Ernst, E. et al., 1991. Impaired blood rheology: A risk factor after stroke? Journal of Internal Medicine, 229, 457–62. Available at: www.ncbi.nlm.nih.gov/pubmed/2040872 [Accessed November 22, 2015].Google Scholar

Ernst, E., 1995. Haemorheological consequences of chronic cigarette smoking. Journal of Cardiovascular Risk, 2, 435–9. Available at: www.ncbi.nlm.nih.gov/pubmed/8749271 [Accessed November 22, 2015].Google Scholar

Fahey, J. L., Barth, W. F., & Solomon, A., 1965. Serum hypervicosity syndrome. JAMA, 192, 464–7. Available at: www.ncbi.nlm.nih.gov/pubmed/14284847 [Accessed November 22, 2015].Google Scholar

Fahraeus, R. & Lindqvist, T., 1931. Viscosity of blood in narrow capillary tubes. American Journal of Physiology, 96, 562–8. Available at: www.ncbi.nlm.nih.gov/pubmed/2040872 [Accessed November 22, 2015].Google Scholar

Fisher, M. & Meiselman, H. J., 1991. Hemorheological factors in cerebral ischemia. Stroke, 22, 1164–9. Available at: www.ncbi.nlm.nih.gov/pubmed/1833861 [Accessed November 22, 2015].Google Scholar

Forconi, S. & Gori, T., 2013. Endothelium and hemorheology. Clinical Hemorheology and Microcirculation, 53, 3–10. Available at: www.ncbi.nlm.nih.gov/pubmed/22951621 [Accessed December 6, 2015].Google Scholar

Gaehtgens, P. & Marx, P., 1987. Hemorheological aspects of the pathophysiology of cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism, 7, 259–65. Available at: www.ncbi.nlm.nih.gov/pubmed/3294863 [Accessed November 22, 2015].Google Scholar

Gori, T. et al., 2015. The distribution of whole blood viscosity, its determinants and relationship with arterial blood pressure in the community: Cross-sectional analysis from the Gutenberg Health Study. Therapeutic Advances in Cardiovascular Disease, 9, 354–65. Available at: www.ncbi.nlm.nih.gov/pubmed/26082340 [Accessed December 11, 2015].Google Scholar

Grotemeyer, K. C. et al., 2014. Association of elevated plasma viscosity with small vessel occlusion in ischemic cerebral disease. Thrombosis Research, 133, 96–100. Available at: www.ncbi.nlm.nih.gov/pubmed/24238841 [Accessed December 6, 2015].Google Scholar

Grotta, J. C. et al., 1986. Red blood cell disorders and stroke. Stroke, 17, 811–7. Available at: www.ncbi.nlm.nih.gov/pubmed/3532433 [Accessed November 22, 2015].Google Scholar

Hayashi, T. et al., 2015. Ischemic stroke in pediatric moyamoya disease associated with immune thrombocytopenia: A case report. Child’s Nervous System, 31, 991–6. Available at: www.ncbi.nlm.nih.gov/pubmed/25663502 [Accessed November 14, 2015].Google Scholar

Hernández-Gilsoul, T. et al., 2013. Pulmonary hypertension secondary to hyperviscosity in a patient with rheumatoid arthritis and acquired von Willebrand disease: A case report. Journal of Medical Case Reports, 7, 232. Available at: www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4015717&tool=pmcentrez&rendertype=abstract [Accessed December 15, 2015].Google Scholar

van Hilten, J. J. et al., 1989. Cerebral infarction in hereditary spherocytosis. Stroke, 20, 1755–6. Available at: www.ncbi.nlm.nih.gov/pubmed/2595739 [Accessed November 22, 2015].Google Scholar